Posted by Michael Wonder on 15 Apr 2021
Alexion's pricey Ultomiris wins backing from England's cost watchdogs thanks to confidential discount
15 April 2021 - Alexion has added a nice piece to Ultomiris’ growth potential ahead of its planned merger with AstraZeneca, scoring backing from England’s drug cost watchdog in a key indication.
The C5 inhibitor now has full coverage on the National Health Service for the treatment of paroxysmal nocturnal haemoglobinuria, thanks to a recommendation from NICE.
It can now be used in patients with high disease activity who have remained stable on the drug’s predecessor Soliris for at least six months.
